Annexon, Inc. Grants Inducement Equity Award to New Employee
Annexon, Inc. announced the grant of an inducement equity award to a new non-executive employee under its 2022 Employment Inducement Award Plan.
Stocks · News reference
Annexon, Inc. announced it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy during the fourth quarter of 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Annexon, Inc. announced the grant of an inducement equity award to a new non-executive employee under its 2022 Employment Inducement Award Plan.
J.P. Morgan reaffirmed its Buy rating on Annexon, Inc. (ANNX) on November 10, 2026.
Annexon, Inc. reported its third quarter 2026 financial results, highlighting progress in its C1q platform and key clinical milestones for its lead candidates, tanruprubart and vonaprument.
Annexin Pharmaceuticals has finalized patient recruitment for its ongoing clinical study, setting the stage for topline data expected by the end of the first quarter of 2027.
Annexon, Inc. will host a virtual investor event on November 3, 2026, to discuss the design and patient population of its ARCHER II Phase 3 clinical trial.